| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2851149 | American Heart Journal | 2010 | 8 Pages |
Abstract
The LMWH enoxaparin combined with reduced dose of UFH (50 U/kg) administration as an adjunctive antithrombotic therapy in STEMI patients undergoing primary PCI with DESs seems to be safe and efficacious. However, randomized clinical trials are needed to confirm this conclusion.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Yong-Jian MD, Seung-Woon MD, Kang-Yin MD, Kanhaiya L. MD, Zhe MD, Yoshiyasu MD, Lin MD, Qun MD, Guang-Ping MD, Sureshkumar MD, Ji-Young MD, Chol Ung MD, Jin-Won MD, Eung Ju MD, Chang Gyu MD, Hong Seog MD, Dong Joo MD, Myung Ho MD, Seung Jung MD,